# OnCo record thymic-epithelial (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/thymic-epithelial/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "thymic-epithelial" ;
  schema:name "Thymoma and thymic carcinoma"@en ;
  schema:alternateName "Thymic epithelial tumours"@en, "TET"@en, "Thymus Cancer"@en ;
  schema:description "Thymoma and thymic carcinoma are rare tumours of the thymus gland in the chest. Thymomas grow slowly, often cause autoimmune diseases such as myasthenia gravis, and are usually cured by surgery; thymic carcinomas behave like other aggressive cancers and have few effective drugs."@en ;
  schema:url <https://onco.cc/cancers/thymic-epithelial/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Thymoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1429863> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1469>, <https://itmig.org/>, <https://www.cancer.gov/types/thymoma/patient/thymoma-treatment-pdq> ;
  onco:tag "gap-fill", "thoracic", "rare" ;
  onco:technologies <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cardio-oncology/> ;
  onco:targets <https://onco.cc/targets/kit/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/imatinib/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/eisai/>, <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/tmb/> ;
  onco:pipeline <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/kc1036/>, <https://onco.cc/drugs/eb-car30-nk/> ;
  onco:standardOfCare <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/imatinib/> .